TG Therapeutics Reports the US FDA's Acceptance of BLA for Ublituximab + Ukoniq (umbralisib) to Treat Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Shots:
- The BLA submission is based on P-III UNITY-CLL trial evaluating ublituximab + Ukoniq (U2) vs obinutuzumab + chlorambucil in a ratio (1:1) in 420 patients with treatment-naive and r/r CLL. The 1EP of the study was PFS
- The trial is being conducted under a SPA agreement with the US FDA. The FDA also notified the company that no advisory committee meeting is planned to discuss the application
- The combination therapy has previously received FTD & ODD from the FDA for the treatment of adult patients with CLL. The anticipated PDUFA date is Mar 25- 2022
Ref: Globe Newswire | Image: TG Therapeutics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com